Literature DB >> 21115397

Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.

Dan Ehninger1, Alcino J Silva.   

Abstract

Tuberous sclerosis (TSC) is a genetic disorder caused by heterozygous mutations in the TSC1 or TSC2 genes and is associated with autism spectrum disorders (ASD) in 20-60% of cases. In addition, altered TSC/mTOR signaling is emerging as a feature common to a subset of ASD. Recent findings, in animal models, show that restoration of the underlying molecular defect can improve neurological dysfunction in several of these models, even if treatment is initiated in adult animals, suggesting that pathophysiological processes in the mature brain contribute significantly to the overall neurological phenotype in these models. These findings suggest that windows for therapeutic intervention in ASD could be wider than thought previously. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115397      PMCID: PMC3075964          DOI: 10.1016/j.molmed.2010.10.002

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  127 in total

1.  The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.

Authors:  R F Lamb; C Roy; T J Diefenbach; H V Vinters; M W Johnson; D G Jay; A Hall
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

Review 2.  Differential translation and fragile X syndrome.

Authors:  P W Vanderklish; G M Edelman
Journal:  Genes Brain Behav       Date:  2005-08       Impact factor: 3.449

3.  The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Authors:  Cory M Johannessen; Elizabeth E Reczek; Marianne F James; Hilde Brems; Eric Legius; Karen Cichowski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

Review 4.  Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.

Authors:  David J Kwiatkowski; Brendan D Manning
Journal:  Hum Mol Genet       Date:  2005-10-15       Impact factor: 6.150

5.  Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex.

Authors:  Patrick F Bolton; Rebecca J Park; J Nicholas P Higgins; Paul D Griffiths; Andrew Pickles
Journal:  Brain       Date:  2002-06       Impact factor: 13.501

6.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

7.  Identification and characterization of the tuberous sclerosis gene on chromosome 16.

Authors: 
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

Review 8.  Autism and tuberous sclerosis.

Authors:  S L Smalley
Journal:  J Autism Dev Disord       Date:  1998-10

Review 9.  A synaptic trek to autism.

Authors:  Thomas Bourgeron
Journal:  Curr Opin Neurobiol       Date:  2009-06-21       Impact factor: 6.627

10.  Deregulation of EIF4E: a novel mechanism for autism.

Authors:  M Neves-Pereira; B Müller; D Massie; J H G Williams; P C M O'Brien; A Hughes; S-B Shen; David St Clair; Z Miedzybrodzka
Journal:  J Med Genet       Date:  2009-06-25       Impact factor: 6.318

View more
  85 in total

1.  PTEN regulation of local and long-range connections in mouse auditory cortex.

Authors:  Qiaojie Xiong; Hysell V Oviedo; Lloyd C Trotman; Anthony M Zador
Journal:  J Neurosci       Date:  2012-02-01       Impact factor: 6.167

Review 2.  Calpain-1 and Calpain-2: The Yin and Yang of Synaptic Plasticity and Neurodegeneration.

Authors:  Michel Baudry; Xiaoning Bi
Journal:  Trends Neurosci       Date:  2016-02-10       Impact factor: 13.837

3.  Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits.

Authors:  Guomei Tang; Kathryn Gudsnuk; Sheng-Han Kuo; Marisa L Cotrina; Gorazd Rosoklija; Alexander Sosunov; Mark S Sonders; Ellen Kanter; Candace Castagna; Ai Yamamoto; Zhenyu Yue; Ottavio Arancio; Bradley S Peterson; Frances Champagne; Andrew J Dwork; James Goldman; David Sulzer
Journal:  Neuron       Date:  2014-08-21       Impact factor: 17.173

Review 4.  Modeling autistic features in animals.

Authors:  Paul H Patterson
Journal:  Pediatr Res       Date:  2011-05       Impact factor: 3.756

5.  Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis.

Authors:  Oak Z Chi; Chang-Chih Wu; Xia Liu; Kang H Rah; Estela Jacinto; Harvey R Weiss
Journal:  Neuromolecular Med       Date:  2015-06-06       Impact factor: 3.843

6.  Longitudinal changes in diffusion properties in white matter pathways of children with tuberous sclerosis complex.

Authors:  Fiona M Baumer; Jae W Song; Paul D Mitchell; Rudolph Pienaar; Mustafa Sahin; P Ellen Grant; Emi Takahashi
Journal:  Pediatr Neurol       Date:  2015-02-16       Impact factor: 3.372

7.  Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice.

Authors:  Adam B Steinmetz; Sarah A Stern; Amy S Kohtz; Giannina Descalzi; Cristina M Alberini
Journal:  J Neurosci       Date:  2017-12-07       Impact factor: 6.167

8.  Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL/6 mice.

Authors:  Peter T Tsai; Emily Greene-Colozzi; June Goto; Stefanie Anderl; David J Kwiatkowski; Mustafa Sahin
Journal:  Behav Genet       Date:  2012-12-12       Impact factor: 2.805

9.  Neurobiology meets genomic science: the promise of human-induced pluripotent stem cells.

Authors:  Hanna E Stevens; Jessica Mariani; Gianfilippo Coppola; Flora M Vaccarino
Journal:  Dev Psychopathol       Date:  2012-11

10.  Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders.

Authors:  Jessica A Burket; Andrew D Benson; Amy H Tang; Stephen I Deutsch
Journal:  Brain Res Bull       Date:  2013-12-01       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.